BRPI0514701A - use of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof - Google Patents

use of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof

Info

Publication number
BRPI0514701A
BRPI0514701A BRPI0514701-8A BRPI0514701A BRPI0514701A BR PI0514701 A BRPI0514701 A BR PI0514701A BR PI0514701 A BRPI0514701 A BR PI0514701A BR PI0514701 A BRPI0514701 A BR PI0514701A
Authority
BR
Brazil
Prior art keywords
isomer
metabolite
pharmaceutically acceptable
acceptable salt
estrogen receptor
Prior art date
Application number
BRPI0514701-8A
Other languages
Portuguese (pt)
Inventor
Taru Blom
Janne Komi
Risto Lammintausta
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20041216A external-priority patent/FI20041216A0/en
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of BRPI0514701A publication Critical patent/BRPI0514701A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

USO DE UM MODULADOR DO RECEPTOR DE ESTROGêNIO SELETIVO, OU UM ISÈMERO, MISTURA DE ISÈMERO, METABóLITO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO Esta invenção diz respeito a um uso de um modulador do receptor de estrogênio seletivo, ou um isómero, mistura de isómero, metabólito ou um sal farmaceuticamente aceitável do mesmo para a fabricação de uma preparação farmacêutica para o uso em um método para o tratamento ou prevenção de deficiência de androgênio ou doenças e distúrbios causados por deficiência de androgênio em um indivíduo masculino.Use of a selective estrogen receptor modulator, or isomer, isomer mixture, metabolite or pharmaceutically acceptable salt thereof This invention relates to the use of a selective estrogen receptor modulator, or an isomer, isomer mixture metabolite or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency or androgen deficiency diseases and disorders in a male subject.

BRPI0514701-8A 2004-09-03 2005-07-20 use of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof BRPI0514701A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60690704P 2004-09-03 2004-09-03
FI20041216A FI20041216A0 (en) 2004-09-21 2004-09-21 A method of treating or preventing an androgen deficiency
PCT/FI2005/000333 WO2006024689A1 (en) 2004-09-03 2005-07-20 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency

Publications (1)

Publication Number Publication Date
BRPI0514701A true BRPI0514701A (en) 2008-06-24

Family

ID=35999733

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514701-8A BRPI0514701A (en) 2004-09-03 2005-07-20 use of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof

Country Status (10)

Country Link
EP (1) EP1786408A4 (en)
JP (1) JP2008511615A (en)
KR (1) KR20070059110A (en)
AU (1) AU2005279178A1 (en)
BR (1) BRPI0514701A (en)
CA (1) CA2578852A1 (en)
MX (1) MX2007002606A (en)
NO (1) NO20071160L (en)
RU (1) RU2007112114A (en)
WO (1) WO2006024689A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121553B1 (en) 2007-02-14 2012-06-27 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US20080312239A1 (en) * 2007-06-13 2008-12-18 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
PL2580210T3 (en) 2010-06-10 2017-09-29 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
CA2972198C (en) 2014-12-29 2023-05-09 Olon S.P.A. Process for the preparation of ospemifene and fispemifene
WO2023175010A1 (en) * 2022-03-15 2023-09-21 Centre D'etude Des Cellules Souches (Cecs) Use of bazedoxifene for increasing muscle survival

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
TW593256B (en) * 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CO5271697A1 (en) * 2000-01-12 2003-04-30 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF AFFECTIONS THAT RESPOND TO AN INCREASE OF TESTOSTERONE
EP1289519B1 (en) * 2000-05-26 2019-02-13 Harry Fisch Methods of treating androgen deficiency in men using clomiphene
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
SI1666033T1 (en) * 2001-11-29 2009-06-30 Gtx Inc Prevention and treatment of androgen-deprivation induced osteoporosis

Also Published As

Publication number Publication date
RU2007112114A (en) 2008-10-10
JP2008511615A (en) 2008-04-17
EP1786408A1 (en) 2007-05-23
MX2007002606A (en) 2007-05-15
KR20070059110A (en) 2007-06-11
AU2005279178A1 (en) 2006-03-09
EP1786408A4 (en) 2010-07-28
CA2578852A1 (en) 2006-03-09
NO20071160L (en) 2007-05-25
WO2006024689A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
BRPI0514701A (en) use of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2007051062A3 (en) Substituted dihydropyridines and methods of use
BRPI0510043A (en) method of treating neuropathic pain using crth2 receptor antagonist
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
BRPI0507966A (en) use of meloxicam for the treatment of respiratory diseases in pigs
WO2009068689A3 (en) Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders
BRPI0618239A8 (en) use of flibanserin for the treatment of premenopausal sexual desire disorders
BR112013003677A2 (en) use of pharmacologically active agent and pharmaceutical dosage form
AR048833A1 (en) PROCEDURE FOR THE TREATMENT OF PREMENSTRUAL DISORDERS AND OTHER FEMALE SEXUAL DISORDERS
WO2006066011A3 (en) Compounds and compositions as modulators of steroidal receptors and calcium channel activities
NO20070742L (en) Progesterone receptor modulators containing pyrrole-oxindole derivatives and their use.
UA95447C2 (en) Method of human female contraception
WO2007025005A3 (en) Sustained release formulations of nalbuphine
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
WO2011157416A3 (en) Transdermal administration of memantine
BRPI0816255A2 (en) Pharmaceutical product, use of the product, method for the prophylaxis or treatment of diseases, and pharmaceutically acceptable composition.
WO2006124681A3 (en) Oral drug delivery system and methods of use thereof
WO2005077122A3 (en) Compounds and compositions as lxr modulators
NO20080936L (en) Transdermal drug delivery devices containing O-desmethylvenlafaxine (ODV) or salts thereof
IS8162A (en) A method of treating or preventing lower urinary symptoms
EA201171035A1 (en) COMPOSITIONS, INCLUDING MODULATORS PDE4, AND METHOD OF THEIR APPLICATION FOR THE TREATMENT, PREVENTION AND SUPPORT OF TUBERCULOSIS
BRPI0516464B8 (en) method for preparing a pharmaceutical product
WO2005092062A3 (en) Compounds for neurodegenerative disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.